Solid Biosciences Inc. SLDB
Solid Biosciences Inc. (Nasdaq: SLDB) is a rare genetic drug developer. Its lead program, SGT-003, is in Phase 3 for Duchenne muscular dystrophy. Its next catalyst on record is SGT-003: FDA meeting to discuss INSPIRE DUCHENNE data package and potential accelerated approval pathway (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SGT-003 — FDA meeting to discuss INSPIRE DUCHENNE data package and potential accelerated approval pathway (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SGT-003 (IMPACT DUCHENNE, randomized placebo-controlled Phase 3) | Duchenne muscular dystrophy | gene therapy | Phase 3 |
| SGT-003 (INSPIRE DUCHENNE, Phase 1/2) | Duchenne muscular dystrophy | gene therapy | Phase 2 |
| SGT-212 (FALCON, Phase 1b) | Friedreich's ataxia | gene therapy | Phase 1 |
| SGT-501 (ARTEMIS, Phase 1b) | catecholaminergic polymorphic ventricular tachycardia | gene therapy | Phase 1 |
| SGT-601 | TNNT2-mediated dilated cardiomyopathy | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.